North America Synthetic Opioids Market

North America Synthetic Opioids Market, By Product Type (Synthetic Opioids (Methadone, Fentanyl, and Meperidine), and Semi Synthetic Opioids (Hydrocodane, Oxymorphone, Oxycodone, Hydromorphone, and Buprenorphine)), By Application (Pain Management and De-Addiction), By Distribution Channel (Retail Outlets and Hospitals), and By Country (U.S. and Canada)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Synthetic opioids are a class of medication that are created in labs with a specific chemical structure. The exact molecules that make up synthetic opioids are wholly man-made, generally in a pharmaceutical laboratory. Synthetic opioids are frequently pressed into pills and sold on the street as fake painkillers. These are used as cutting agents in heroin and cocaine. Overdosing on synthetic opioids happens frequently due to their potency.

Synthetic opioids including fentanyl, its derivatives, and recently developed analogues arewidely available in recent years in the market for recreational drugs. The synthetic phenylpiperidine known as fentanyl has both analgesic and anaesthetic effects. It can be purchased separately, added as an adulterant to heroin, cocaine, and amphetamines, or used as a component of illegal prescription drugs. Numerous other potent synthetic opioids, many of which have chemical structures that do not resemble morphine or fentanyl but are active at the -opioid receptor, have recently appeared on the illicit drug market in addition to fentanyl and the fentanyl analogues such as carfentanyl, acetylfentanyl, butyrylfentanyl, and furanylfentanyl. The benzamide-based opioids U-47700 and AH-7921, tianeptine, and MT-45 are among new synthetic opioids.

Market Dynamics

U.S. Government agencies like the Drug Enforcement Administration have put regulations in effect to reduce the number of deaths in the U.S. caused due to synthetic opioid overdoses, and this is expected to drive the North America synthetic drugs market growth over the forecast period.

Regulations

Many synthetic opioids are currently controlled under the Controlled Substances Act

The U.S. Drug Enforcement Administration temporarily placed U-47700, isotonitazene, and several other substances that are structurally related to fentanyl such as acetyl fentanyl, butyryl fentanyl, beta-hydroxythiofentanyl, and furanyl fentanyl, in Schedule I of the Controlled Substances Act

In February 2018, the DEA temporarily placed fentanylrelated substances in Schedule I of the Controlled Substances Act.

Other synthetic opioid substances may be subject to prosecution under the Controlled Substance Analogue Enforcement Act which allows noncontrolled substances to be treated as Schedule I substances if certain criteria are met

The U.S. Drug Enforcement Administration has successfully investigated and prosecuted individuals trafficking and selling these dangerous substances using the Controlled Substances Analogue Enforcement Act

Key features of the study:

This report provides in-depth analysis of the North America synthetic opioids market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the North America synthetic opioids market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study are Johnson & Johnson Services, Inc., Purdue Pharma L.P., Hikma Pharmaceuticals PLC, AbbVie Inc., Sanofi, Sun Pharmaceutical Industries Ltd, Pfizer, Inc., AstraZeneca Plc., Mallinckrodt Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Endo Pharmaceuticals Inc., and Boehringer Ingelheim International GmbH.

Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

North America synthetic opioids market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the North America synthetic opioids market

Detailed Segmentation:

North America Synthetic Opioids Market, By Product Type:

Synthetic Opioids

Methadone

Fentanyl

Meperidine

Semi Synthetic Opioids

Hydrocodane

Oxymorphone

Oxycodone

Hydromorphone

Buprenorphine

North America Synthetic Opioids Market, By Application:

Pain Management

De-Addiction

North America Synthetic Opioids Market, By Distribution Channel:

Retail Outlets

Hospitals

North America Synthetic Opioids Market, By Country:

U.S.

Canada

Company Profiles

Johnson & Johnson Services, Inc.*

Company Highlights

Products Portfolio

Key Highlights

Financial Performance

Strategies

Purdue Pharma L.P.

Hikma Pharmaceuticals PLC

AbbVie Inc.

Sanofi

Sun Pharmaceutical Industries Ltd

Pfizer, Inc.

AstraZeneca Plc.

Mallinckrodt Pharmaceuticals

Teva Pharmaceutical Industries Ltd.

Endo Pharmaceuticals Inc.

Boehringer Ingelheim International GmbH.

“*” marked represents similar segmentation in other categories in the respective section.